Azione KYTX KYVERNA THERAPEUTICS, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Kyverna Therapeutics, Inc.

Azioni

KYTX

US5019761049

Mercato chiuso - Nasdaq
Altri mercati azionari
 22:00:00 27/06/2024 		Variaz. 5gg Var. 1 gen.
7,36 USD +1,24% Grafico intraday di Kyverna Therapeutics, Inc. -8,34% 0,00%
20/06 Aggiornamento settoriale: titoli del settore sanitario in rialzo nel tardo pomeriggio MT
20/06 Kyverna Therapeutics ottiene l'autorizzazione della FDA per la domanda di sperimentazione di nuovi farmaci per KYV-101 per il trattamento della sindrome della persona rigida MT

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to S&P Global BMI Index
Sector Update: Health Care Stocks Higher Late Afternoon
Kyverna Therapeutics Gets FDA Investigational New Drug Application Clearance for KYV-101 to Treat Stiff-Person Syndrome
Kyverna Therapeutics Shares Rise 13% After FDA Clearance for KYV-101
Kyverna Therapeutics Gets FDA IND Clearance for KYV-101
Kyverna's KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
Kyverna Therapeutics, Inc.'s KYV-101 Receives U.S. FDA IND Clearance for Treatment of Patients with Treatment-Refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome Published in Proceedings of the National Academy of Sciences (PNAS)
Kyverna Therapeutics, Inc. Announces First-In-Disease Use of it's KYV-101 in Patient with Severe Stiff-Person Syndrome Published in Results
KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation
Sector Update: Health Care Stocks Decrease Late Afternoon
Sector Update: Health Care
Kyverna Therapeutics Shares Fall After Early Data on CAR T Cell Therapy Candidate
KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
Kyverna Therapeutics Q1 Loss Narrows
Kyverna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Nasdaq's revenue beats on strong demand for fintech products
First-in-Disease Use of Kyverna Therapeutics KYV-101 in Patients with Progressive Multiple sclerosis Published in Med1
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione KYTX
  4. Notizie Kyverna Therapeutics, Inc.
  5. Altre lingue